# SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

> **NCT00180310** · PHASE3 · COMPLETED · sponsor: **Abbott Medical Devices** · enrollment: 300 (actual)

## Conditions studied

- Coronary Disease
- Coronary Artery Disease
- Coronary Restenosis

## Interventions

- **DEVICE:** XIENCE V® Everolimus Eluting Coronary Stent
- **DEVICE:** TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent

## Key facts

- **NCT ID:** NCT00180310
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-07
- **Final completion:** 2011-02
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2011-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00180310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00180310, "SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00180310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*